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Fibrosis can affect almost all tissues and organs, it often represents the terminal stage of chronic diseases, and it is regarded as a
major health issue for which efficient therapies are needed. Tissue injury, by inducing necrosis/apoptosis, triggers inflammatory
response that, in turn, promotes fibroblast activation and pathological deposition of extracellular matrix. Acylated and unacylated
ghrelin are the main products of the ghrelin gene.The acylated form, through its receptor GHSR-1a, stimulates appetite and growth
hormone (GH) release. Although unacylated ghrelin does not bind or activate GHSR-1a, it shares with the acylated form several
biological activities. Ghrelin peptides exhibit anti-inflammatory, antioxidative, and antiapoptotic activities, suggesting that they
might represent an efficient approach to prevent or reduce fibrosis. The aim of this review is to summarize the available evidence
regarding the effects of acylated and unacylated ghrelin on different pathologies and experimental models in which fibrosis is a
predominant characteristic.
1. Introduction
Repair of damaged tissues is a complex physiological pro-
cess that results in the deposition of extracellular matrix
(ECM) components by resident fibroblasts [1]. Although the
deposition of ECM proteins is normally a transient event,
repeated tissue injuries in chronic pathologies or dysregu-
lation of this process can lead to fibrosis and, eventually, to
organ dysfunction [2]. Fibrosis can affect almost all tissues
and organs, including heart, liver, kidney, lungs, and skin,
therefore representing amajor health issue for which efficient
therapies are needed.
Regardless of the specific fibrotic disease and organs
affected, the mechanisms involved in the progression of this
pathology are very similar. Indeed, damaged tissue repair
can be recapitulated in four overlapping phases, hemostasis,
inflammation, proliferation, and remodeling in which several
cell types, closely interconnected to each other, play an
important role [3]. During the phases of hemostasis and
inflammation, platelets secrete cytokines, including platelet-
derived growth factor (PDGF) and transforming growth
factor-𝛽 (TGF-𝛽) that, in turn, recruit macrophages, neu-
trophils, and natural-killer cells to the site of injury. These
cells, besides removing dead cells, debris, and pathogens,
release cytokines that trigger activation and proliferation of
resident fibroblasts, thus affecting ECM production [4]. For
example, macrophages release TGF-𝛽1 that controls a wide
spectrum of activities, such as promoting fibroblast differ-
entiation into active myofibroblasts, inducing ECM protein
expression [5, 6], and repressing the expression of matrix
metalloproteinases (MMPs), key proteins able to degrade
several ECM components [7]. In addition, macrophages
release tumor necrosis factor-𝛼 (TNF-𝛼) and interleukin-1𝛽
(IL-1𝛽) that promote fibroblast activation and fibrotic tissue
deposition [2]. Tissue damage and inflammation increase
reactive oxygen species (ROS) production, which, in turn,
contributes to fibrosis, enhancing the secretion of fibrogenic
factors [8].
Acylated and unacylated ghrelin are circulating peptide
hormones encoded by the ghrelin gene which are mainly
released from the stomach during fasting [9]. The 117-amino
acid preproghrelin undergoes proteolytic cleavages leading to
the mature ghrelin peptides and to another biological active
peptide named obestatin [10]. The acylated form, through
high affinity binding to the growth hormone secretagogue
receptor type 1a (GHSR-1a), induces GH release and pro-
motes food intake, adiposity, and positive energy balance [11–
13]. Alongside its role in feeding and energy homeostasis,
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Table 1: Changes of acylated ghrelin, unacylated ghrelin, and obestatin blood concentrations in human pathological conditions leading to
organ fibrosis.
Pathological condition Acylated ghrelin Unacylated ghrelin Obestatin Notes Reference
Chronic heart failure
(CHF)
↑ nd nd [46]
↓ nd nd Acylated ghrelin levels positivelycorrelate with favorable prognosis [47]
Chronic hepatitis C ↓ nd nd Acylated ghrelin levels negativelycorrelate with fibrosis severity [48]
Alcoholic hepatitis ↓ nd nd Acylated ghrelin levels negativelycorrelate with fibrosis severity [48]
Nonalcoholic fatty liver
disease (NAFLD) nd nd = [90]
Nonalcoholic
steatohepatitis (NASH)
= ↑ = NASH versus non-NASH (amongNAFLD patients)
[50]
↑ = ↑ Severe NASH (fibrosis index ≥2) versusnot severe NASH (fibrosis index <2)
Chronic obstructive
pulmonary disease (COPD) ↑ nd nd
Acylated ghrelin levels positively
correlate with inflammation [51]
Systemic sclerosis ↓ ↓ nd [52]
ghrelin exerts also many other biological activities, including
cardioprotection and enhancement of cardiac function [14],
a strong anti-inflammatory activity [15], antioxidant activity
on several cell types and tissues such as liver, heart, and
lung [16–19], and neuroprotective activities [20].The acylated
ghrelin anti-inflammatory function mainly depends on its
direct effect on T lymphocytes and monocytes, in which it
inhibits the expression of proinflammatory cytokines such as
IL-1𝛽, IL-6, and TNF-𝛼 [21].
Acylation of ghrelin is essential for its binding to GHSR-
1a, since the unacylated form does not activate this receptor,
unless administered at very high concentrations, in which
case it acts as a functional agonist [22–25]. However, both
acylated and unacylated ghrelin share high affinity binding
sites in a number of cell lines and tissues, where they mediate
several activities, such as protection from apoptosis and
oxidative injury [26–32], stimulation of cell differentiation
[33–36], induction of proliferation [30, 37–39], and protec-
tion of skeletal muscles from wasting [40–42]. These effects
suggest the presence of a not yet identified common receptor
of both acylated and unacylated ghrelin. In addition, some
biological activities are elicited only by the unacylated but
not the acylated form of ghrelin, suggesting the existence of a
specific receptor for unacylated ghrelin [39, 43–45].
Circulating levels of acylated and unacylated ghrelin are
often altered in pathological states associated with fibro-
sis and this suggests a role for these hormones in tissue
homeostasis and/or in etiology of these conditions ([46–52],
Table 1).
2. Acylated and Unacylated Ghrelin as
Antifibrotic Factors
2.1. Heart. The massive deposition of collagen in the
heart that occurs upon several stimuli, such as cardiomy-
ocyte death, inflammation, hypertension-induced enhanced
workload, hypertrophy, or chemotherapy with doxorubicin,
plays a crucial role in cardiac remodeling after heart injury
and may contribute to ventricular arrhythmias, left ventricu-
lar dysfunction, heart failure, and sudden cardiac death [53].
Together with inflammation, cardiac fibroblasts, themost
abundant cells in the heart, are the main players in cardiac
remodeling: upon injury they undergo proliferation and
synthesize collagen to replace the necrotic or apoptotic
cardiomyocytes [53].
Due to the antiapoptotic and anti-inflammatory activity
of ghrelin, several researchers investigated the antifibrotic
effect of acylated and unacylated ghrelin in different mod-
els of cardiac injury. Doxorubicin, an antibiotic used in
chemotherapy, alters cardiomyocytes energymetabolism and
induces their apoptosis, thus determining myocardial fibro-
sis, which eventually results in cardiomyopathy and conges-
tive heart failure [54]. Accordingly with the in vitro data on
the cardioprotective effect of acylated and unacylated ghrelin
against doxorubicin-induced apoptosis of cardiomyocytes
[26], it has been recently demonstrated that both peptides
are effective in inhibiting the cardiotoxicity of this drug also
in vivo [55, 56]. Unacylated ghrelin displays antiapoptotic
effects on cardiomyocytes through the activation of the
prosurvival ERK1/2 and PI3K/Akt signaling pathways ([26,
55], Figure 1). Acylated ghrelin seems to play an important
role in the regulation of autophagy, a cellular pathway
involved in protein and organelle degradation. Although this
cellular pathway is normally a protective mechanism, exces-
sive autophagy can destroy essential cellular components
and eventually induce apoptosis [57]. Doxorubicin treatment
induces oxidative stress, autophagy, apoptosis, and, finally,
cardiac dysfunction and collagen deposition in the heart
[56, 57]. In this experimentalmodel of cardiac injury, acylated
ghrelin inhibits ROS-induced autophagy and cardiomyocyte
death through the inhibition of AMPK and activation of p38-
MAPK pathway ([56], Figure 1), thus leading to a decrease
of doxorubicin-induced fibrosis and cardiac dysfunction.
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Figure 1: Schematic representation of the molecular pathways involved in the antifibrotic activity of ghrelin and unacylated ghrelin. See text
for details.
The antifibrotic effects of acylated and unacylated ghrelin
have been demonstrated in other experimental models of
cardiac injury, such as isoproterenol administration, myocar-
dial infarction (MI), and spontaneous or diabetes-associated
hypertension [58–62].The subacute injection in rats of the 𝛽-
adrenergic agonist isoproterenol induces myocardial injury
and fibrosis and increases myocardial ghrelin expression and
plasmatic acylated ghrelin levels [58, 59]. In this model,
acylated ghrelin treatment ameliorates myocardial function
and reduces fibrosis, although the mechanisms of such a
protection have not been elucidated [59]. The unacylated
form of the peptide displays similar effects, suggesting that
the antifibrotic activity of ghrelin is mediated by both GHSR-
dependent and GHSR-independent pathways [59].
Ghrelin has a positive effect on cardiac remodeling and
cardiac function also in rats undergoing MI by coronary
artery ligation. MI induces a strong increase in tissutal IL-
1𝛽 and TNF-𝛼 that is inhibited by the chronic administration
of ghrelin [60]. Ghrelin also blunts the induction of MMP-
2 and MMP-9 that could be viewed as an inhibition of
overall fibroblasts activity [60]. However, in spontaneously
hypertensive rats, the synthetic GH-secretagogue hexarelin
prevents cardiac fibrosis by inducing, rather than by inhibit-
ing, MMP-2 and MMP-9 activity [61]. Notably, unacylated
ghrelin, despite reducing cardiac fibrosis in diabetic mice,
has no effect on other MMPs involved in cardiac fibrosis
development such as MMP-8 and MMP-13 [62]. The effect
of unacylated ghrelin treatment was in fact investigated also
in db/db diabetic mice compared to nondiabetic mice [62],
since cardiac fibrosis is also observed in diabetic patients
without hypertension [63]. In this model of diabetic mice,
unacylated ghrelin impairs collagen accumulation by upreg-
ulating adiponectin cardiac expression [62], which is known
to prevent myocardial hypertrophy and fibrosis [64, 65].
2.2. Liver. In liver, hepatitis C or B viral infections, autoim-
mune diseases, alcohol abuse, and nonalcoholic fatty liver
disease (NAFLD) can progress to a severe fibrotic disease
in which parenchymal tissue is replaced by nonfunctional
fibrotic tissue, a condition defined as cirrhosis [66]. Removal
of the causative agent, such as viral infections, could revert
liver fibrosis, but in the case of autoimmune diseases and
NAFLD the causative agent is not clearly defined and the
identification of new agents that could modulate this process
is of pivotal importance [67].
In patients with alcoholic hepatitis and chronic hepatitis
C, plasmatic ghrelin levels are lower than in healthy subjects
and negatively correlate with the severity of fibrosis ([48],
Table 1). Circulating ghrelin levels also correlate with other
hepatic fibrotic diseases; however, in the case of patients
with NAFLD, a worsening of the fibrotic stage is associated
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with high plasmatic concentration of both acylated and
unacylated ghrelin ([50], Table 1). Interestingly, a screening
of miRNAs expression in visceral adipose tissue of NAFLD
patients revealed that miR-132, of which the ghrelin gene is
a predicted target, is downregulated in nonalcoholic steato-
hepatitis (NASH) compared to non-NASH patients [68],
although a biological validation of this relationship still needs
to be performed.
Although the causative relationship between ghrelin cir-
culating levels and NAFLD is not defined, ghrelin might have
a therapeutic potential in this and other hepatic pathologies,
as demonstrated in several experimental models. The most
used models to induce hepatic fibrosis include CCl
4
or
thioacetamide (TAA) administration to rodents, which lead
to oxidative stress-mediated liver cirrhosis [69]. Another
model to induce liver fibrosis consists in bile duct ligation
(BDL), which causes accumulation of hydrophobic bile acids
in the liver, leading to ROS formation, oxidative damage,
inflammatory cell accumulation, and the increase of serum
proinflammatory cytokines [70]. In addition, NAFLD may
be reproduced in rats by feeding animals with a high-fat
diet, thus inducing liver fat accumulation, inflammation, and
cellular necrosis [71]. In this model, ghrelin treatment blunts
the induction of TNF-𝛼 and IL-6 expression, counteracts
hepatic oxidative stress, and inhibits hepatic cell apoptosis
[72]. The beneficial effects of ghrelin on liver injury and
fibrosis have been pointed out by other studies as well.
Indeed, in rats with chronic hepatic fibrosis caused by BDL,
ghrelin administration prevents hepatic damage by blunting
the BDL-induced increase of TNF-𝛼, IL-1𝛽, and IL-6 plasma
levels [73]. Moreover, ghrelin treatment impairs neutrophil
infiltration and diminishes the amount of myofibroblast
accumulation in the injured liver [48, 73]. Accordingly, ghre-
lin downregulates the expression of collagen-𝛼1 and TGF-
𝛽1 in primary hepatic stellate cells (HSC), the main hepatic
fibrogenic cells [48], resulting in a diminished collagen
deposition [48, 73]. Ghrelin features anti-inflammatory and
antifibrotic effects also in TAA-induced hepatic injury in
rats where it attenuates liver injury and collagen deposition
through inhibition of hepatic cell apoptosis and antioxidative
activity, in a way partially mediated by the induction of nitric
oxide (NO) [49].
Finally, the physiological role of the ghrelin gene in the
establishment of liver fibrosis was investigated exploiting
ghrelin knock-out mice that display muchmore severe CCl
4
-
induced liver injury and fibrosis compared to wild type
animals, suggesting that endogenous ghrelin is required for
a proper response to liver damage [48].
2.3. Kidneys. Ghrelin is expressed in kidneys and its expres-
sion is altered in pathological conditions such as glomeru-
lopathies, in particular in the proliferative form, in which
the immunoexpression of ghrelin is abated [74]. Moreover,
the expression of ghrelin negatively correlates with the
profibrotic protein endothelin-1 and interstitial inflammatory
cell infiltration, suggesting that the loss of ghrelin could
contribute to the development of renal interstitial fibrosis,
which is the common feature of different end-stage renal
diseases [74].
The renin-angiotensin system (RAS) is a well-known reg-
ulator of blood pressure and contributes to the development
of target organ damage due to hypertension. Angiotensin-II
(AngII) is themainmediator of RAS-induced chronic kidney
damage through multiple mechanisms, including promotion
of inflammation, fibrosis, oxidative stress, and senescence
[75]. Indeed, in the experimental model of chronic kidney
disease induced by AngII infusion, the kidneys display
increased ROS and an accelerated tissue senescence [76, 77].
In addition, treated mice express higher levels of TGF-𝛽
and plasminogen activator inhibitor-1 (PAI-1) than saline-
infused animals [78]. In this model, ghrelin impairs renal
tubular damage, fibrosis development, and senescence by
both reducing the oxidative stress and maintaining the
redox state. This is mediated by the induction of UCP2 and
PGC1𝛼 that affect ROS production andmitochondriogenesis,
respectively ([78], Figure 1).
The antifibrogenic activity of ghrelin was demonstrated
also in a rat model of renal damage obtained by unilateral
ureteral obstruction (UUO), which results in tubular injury
and cell death, with interstitial macrophage infiltration [79].
In this model, ghrelin protects renal tubular cells from
apoptosis, impairs macrophage infiltration, and reduces the
induction of the proinflammatory cytokines IL-1𝛽, TNF-
𝛼, and monocyte chemoattractant protein-1 (MCP-1) [80].
Moreover, this work demonstrates that ghrelin attenuates
renal fibrosis by inhibiting fibroblast differentiation and
by blocking epithelial mesenchymal transition (EMT), thus
stabilizing the epithelial phenotype [80]. The mechanisms
through which ghrelin elicits its antifibrotic activity involve
the reduction of collagen I/III, fibronectin, and 𝛼-SMA
expression via inhibition of the TGF-𝛽1/Smad3 signaling
pathway [80].
2.4. Lungs. Lung fibrosis occurs as a consequence of acute
lung injury leading to persistent respiratory failure. Lung
fibrosis is usually differentiated into distinct types, includ-
ing diffuse fibrosing alveolitis, diffuse interstitial fibrosis,
and idiopathic pulmonary fibrosis, which is considered the
most common and severe form of pulmonary fibrosis [81].
Currently, there are no therapies to counteract acute lung
injury progression and lung transplantation remains the only
possible intervention in end-stage disease [81].
Acute lung injury is characterized by the damage of
the alveolar capillary barrier, neutrophil accumulation, and
the induction of proinflammatory cytokines, followed by
devastating lung fibrosis [82, 83]. In particular, the exfoliation
of alveolar epithelial cells from alveolar septa leads to the
activation of fibroblasts and the subsequent massive ECM
deposition [82].
Cecal ligation and puncture (CLP), the most used tech-
nique to induce peritonitis and sepsis, also induces lung
injury and fibrosis as direct consequence of hypoxemia,
neutrophilic inflammation, and alveolar edema [83].
In CLP-treated rats, ghrelin attenuates acute lung injury
and mortality through inhibition of nuclear factor- (NF-)
𝜅B activity ([84], Figure 1). NF-𝜅B is a transcription factor
that regulates gene expression of several cytokines, including
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TNF-𝛼, IL-6, IL-1, and IL-8 [85]. Accordingly, treatment with
ghrelin reduces pulmonary levels of TNF-𝛼 and IL-6 in CLP-
treated rats [84].
Another experimental model used to induce acute lung
injury in rodents is the intratracheal injection of bleomycin
that promotes massive cell death, neutrophil and lymphocyte
infiltration, cytokine production, and fibrosis [83, 86]. In
bleomycin-treated mice, ghrelin administration improves
animal survival in a dose-dependent manner and maintains
lung architecture by reducing fibrosis [86]. This antifibrotic
activity is due to the impairment of neutrophil infiltration and
accumulation in bronchoalveolar lavage fluid and through
the inhibition of proinflammatory cytokines and of IGF-1
release, which promotes collagen production by fibroblasts
[86]. In addition, the inhibition of alveolar epithelial cell
death, observed in ghrelin-treated mice, represents another
mechanism that contributes to ghrelin antifibrotic effects,
since the prevention of the denudation of alveolarmembranes
impairs the subsequent fibrosis establishment [86].
In the same model of lung fibrosis, the traditional
Japanese herbal medicine rikkunshito, known to stimulate
a strong secretion of ghrelin, reduces lung fibrosis and
ameliorates the systemic cachectic condition [87]. However,
rikkunshito effects are only partially due to the associated
ghrelin increase, since it maintains its protective effects also
in mice devoid of the ghrelin gene [88].
2.5. Systemic Sclerosis. Systemic sclerosis, or scleroderma, is
an autoimmune chronic connective tissue disease character-
ized by extensive fibrosis of the skin and internal organs,
including lungs, gastrointestinal tract, kidneys, and heart
[52]. Plasmatic levels of acylated and unacylated ghrelin are
lower in systemic sclerosis patients than in healthy controls
and even lower in patients with interstitial lung disease,
suggesting that acylated ghrelin levels inversely correlate with
tissue fibrosis ([52], Table 1). Consistently, acylated ghrelin
treatment of fibroblasts isolated from systemic sclerosis
patients reduces TGF-𝛽1 expression and collagen production
[52].
Skin scleroderma might be experimentally induced in
mice by subcutaneous injections of bleomycin that result
in increased dermal thickness, a higher number of 𝛼-SMA-
positive myofibroblasts, and greater infiltration of inflamma-
tory cells. All these effects are prevented by both acylated and
unacylated ghrelin [89]. Taken together, these data suggest
that restoring normal circulating acylated andunacylated lev-
els might efficiently contrast the fibrosis induced by systemic
sclerosis.
3. Conclusions
Fibrosis is an intrinsic response to chronic injury, main-
taining organ integrity when extensive necrosis or apopto-
sis occurs. With protracted damage, fibrosis can progress
towards excessive scarring and organ failure. To date, no satis-
factory treatments are available. Anti-inflammation strategies
are one of the possible therapeutic approaches to fibrosis.
Acylated ghrelin has a potent anti-inflammatory activity and
its ability to inhibit proinflammatory cytokines expression
and release has been demonstrated by a large number of
studies, both in vitro and in vivo [15]. Most of the studies
on the antifibrotic effects of acylated and unacylated ghrelin
agree that the mechanism of action includes the reduction of
inflammation. However, also their effect on oxidative stress
reduction plays a crucial role in repressing the formation
of fibrosis, and their broad antiapoptotic activity surely
contributes inmaintaining organ structure and function.This
has, however, raised a doubt that if they inhibit apoptosis also
in myofibroblasts, this could help, instead of hinder, fibrosis
[67].
Circulating levels of ghrelin are often altered in patholo-
gies characterized by the presence of fibrosis; however, it is
difficult to discern a causative effect between ghrelin levels
and fibrosis, as it is plausible that alterations in ghrelin
levels reflect body mass and/or body energy metabolism.
This is particularly possible in pathologies co-occurring with
cachexia, such as heart and renal failure, inwhich the increase
of ghrelin may represent a compensatory mechanism of the
organism in the attempt at re-establishing optimal energetic
balance or the establishment of ghrelin resistance [42]. How-
ever, in pathologies such as scleroderma, in which fibrosis
affects the gastrointestinal tract, it cannot be excluded that
the altered levels of ghrelin are a direct consequence of the
altered gut condition.
Based on the studies reviewed herein, ghrelin, both in its
acylated and unacylated forms, acts at least at two different
levels. On one side, ghrelin peptides reduce the infiltration of
inflammatory cells in the injured tissue and the subsequent
release of cytokines responsible for fibroblast activation.
On the other side, they directly affect fibroblast activity by
reducing collagen production through the inhibition of TGF-
𝛽 signaling pathway.
In conclusion, ghrelin peptides and their analogues
appear to be promising in the treatment of fibrosis, although
their safety and efficacy in long-term use still need to be
elucidated.
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